



active pharmaceutical ingredients*

Commercial scale

Antitubercular

Pyrazinamide[#]

Isoniazid⁺

Rifampicin⁺

Antimalarial

Artesunate

Arteether

Artemether

Dihydroartemisinin

Antihypertensive

Lisinopril dihydrate⁺

Losartan potassium⁺

Antiepileptic

Sodium valproate

Valproic acid⁺

Antiosteoporotic

Alendronate sodium⁺

Zoledronic acid

Macrolides

Azithromycin⁺

Erythromycin base[#]

Erythromycin estolate[#]

Erythromycin ethylsuccinate⁺

Erythromycin oxime (intermediate)

Erythromycin phosphate

Erythromycin propionate

Erythromycin stearate⁺

Roxithromycin

Sedative, Hypnotic

Zopiclone[#]

Antidepressant

Venlafaxine hydrochloride⁺

Antihistaminic

Cetirizine dihydrochloride⁺

Antithrombotic

Clopidogrel bisulphate⁺



intermediates for active pharmaceutical ingredients*

Pilot scale

Carvedilol - Antihypertensive

Clarithromycin - Antibiotic

Pioglitazone hydrochloride - Antidiabetic

Rosiglitazone maleate - Antidiabetic

Valsartan - Antihypertensive

R & D scale

Lumefantrine - Antimalarial

Pamidronate disodium - Antiosteoporotic

Perindopril erbumine - Antihypertensive

Zolpidem tartrate - Hypnotic

Development

Benazepril hydrochloride - Antihypertensive

Candesartan - Antihypertensive

Desvenlafaxine - Antidepressant

Glipizide - Antidiabetic

Irbesartan - Antihypertensive

Levocetirizine - Antihistaminic

Rifabutin - Antitubercular

Rifapentine - Antitubercular

Ramipril - Antihypertensive

Risedronic acid - Antiosteoporotic

Telmisartan - Antihypertensive

US DMF / EU CoS / Russian Registration

+ CTD filing under process

*The Technical and Physical manufacturing capabilities exist with us for the above APIs and their intermediates. However these products will be offered only to the markets where any product or process patents are not infringing. During the validity of a patent the research quantities for developing products for regulatory submissions will only be offered to countries where such exemption exists (Hatch Waxman Act / Bolar exemption). While Calyx offers to work with the clients on Patent Status Verification, the final responsibility vests with the buyer. Recipients are requested to make their evaluation and determination as to the patent status prior to their use of the information or materials in their respective jurisdiction. Products under patent offered only for exempted research, clinical and development purposes. Only non-infringing products and processes are offered, subject to patent status verification by client.

Calyx Chemicals & Pharmaceuticals Limited

Regd. Office: Unit No.2, Marwah's Complex, Marwah Estate, Saki Vihar Road, Andheri (E), Mumbai 400072, India.

Tel: 91-22-28031500, Fax: 91-22-66466817

Corp. Office: A 37/38, MIDC Phase 1, Golavli, Kalyan Shil Road, Dombivli (E), Dist. Thane 421203, India. Tel: 91-251-2438310, Fax: 91-251-2438726.

New Jersey: Tel: 732-579-8569, Fax: 732-321-6562 Los Angeles: Tel: 213-291-7773, Fax: 775-514-1230, Connecticut: Tel 860-910-4279, 860-908-3177

Email: sales@calyxindia.com, crams@calyxindia.com, sales@calyxusa.com, crams@calyxusa.com, www.calyxindia.com